Daiichi Sankyo at ESMO (Kyle LaHucik for Endpoints News)
October 20, 2023 05:05 AM EDTUpdated 11:17 AM
Deals

Mer­ck dou­bles down on AD­Cs with $4B up­front to Dai­ichi Sankyo, go­ing for ‘same in­ten­si­ty’ as megablock­buster Keytru­da

Amber Tong

Kyle LaHucik

Senior Reporter

MADRID — Mer­ck is com­mit­ting $4 bil­lion up­front to team up with Dai­ichi Sankyo on a trio of an­ti­body-drug con­ju­gates, adding fu­el to a space …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen

Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves

Paci­ra ab­sorbs GQ Bio for $32M; Lay­offs at BMS, Ei­sai and CRISPR Ther­a­peu­tics

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times